Faculty profile

Brian Conway

ResearcherSimon Fraser University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Simon Fraser University directory, so their courses and email address may be missing. Find their university profile.

Brian Conway

Researcher

Health Sciences

Simon Fraser University

Burnaby, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
20 publications in the last five years, latest in 2026.
Senior (last) author on 9 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Community Partnerships Hepatitis C Virus Inner City People Who Use Drugs

Latest papers

Worldwide Impact of ACIP's 2025 Overhaul.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
Addressing digital exclusion to improve access to HIV and viral hepatitis care for people who experience criminalization: a mixed methods evaluation of a quality improvement project.
International journal for equity in health · 2025
Achieving the UNAIDS 95-95-95 targets: a right, not a privilege.
AIDS (London, England) · 2025 · senior author

All 20 publications

Latest funding

Engaging Community Partners to Co-Create a Plan for HCV Elimination in Vancouver's Inner City
CIHR · 2024 · Nominated PI
$19,986
Optimizing STBBI health outcomes through precision health
CIHR · 2024 · Co-investigator
$20,000
Optimizing STBBI health outcomes through precision health
CIHR · 2024 · Co-investigator
$1,997,416

All 12 grants and awards

20 publications.

Worldwide Impact of ACIP's 2025 Overhaul.

Bont L, Conway B, Mazur N

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

DOI: 10.1093/cid/ciag043 PMID: 41607304

Addressing digital exclusion to improve access to HIV and viral hepatitis care for people who experience criminalization: a mixed methods evaluation of a quality improvement project.

Tiwana A, Gale N, Mahay M, Barker T, Hasdell R, Young P, Korchinski M, Schmitz D, Luster D, Ramji A, MacIsaac J, Conway B, Fraser C, Bartlett S

International journal for equity in health2025

DOI: 10.1186/s12939-025-02648-3 PMID: 41331782

Achieving the UNAIDS 95-95-95 targets: a right, not a privilege.

Wiesmann C, Conway B

AIDS (London, England)2025Senior author

DOI: 10.1097/qad.0000000000004350 PMID: 41235653

Understanding the clinical implications of low-level viremia in ART-treated individuals.

Conway B, Tebas P, Slama L

AIDS (London, England)2025First author

DOI: 10.1097/qad.0000000000004291 PMID: 40755212

CHIME: Sofosbuvir/Velpatasvir (S/V) for the Treatment of HCV Infection Among Vulnerable Inner-City Residents.

Conway B, Yi S, Truong D

Journal of viral hepatitis2025First author

DOI: 10.1111/jvh.70057 PMID: 40682422

Community Pop-Up Clinic: Cascade of Care and HCV Treatment of Vancouver's Inner-City PWID Populations.

Yi S, Wiesmann C, Truong D, Sharma S, Conway B

Journal of viral hepatitis2025Senior author

DOI: 10.1111/jvh.14023 PMID: 39425540

Beyond virologic suppression.

Conway B, Wiesmann C, Pongpirul K

AIDS (London, England)2025First author

DOI: 10.1097/qad.0000000000004063 PMID: 39878671

The challenge of normalizing vaccine behaviors in the postpandemic era.

Wiesmann C, Conway B

AIDS (London, England)2025Senior author

DOI: 10.1097/qad.0000000000004064 PMID: 39787485

Long-term outcome in people who use drugs successfully treated for hepatitis C infection with glecaprevir/pibrentasvir.

Yi S, Truong D, Conway B

Journal of virus eradication2024Senior author

DOI: 10.1016/j.jve.2024.100569 PMID: 39807127

Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis.

Cornberg M, Hüppe D, Sarrazin C, Ahumada A, Jorquera Plaza F, Mariño Z, Otano JIU, Conway B, Myles L, Ramji A, Abergel A, Asselah T, Larrey D, Aghemo A, Andreoni M, Gasbarrini A, Lampertico P, Persico M, Villa E, Carmiel M, Chodick G, Weil C, Bhagat A, Bondin M, Butrymowicz I, Song Y, Semizarov D, Sonparote S, Llamas C, CREST Study Group

Advances in therapy2024

DOI: 10.1007/s12325-024-02996-6 PMID: 39470876

Engaging Community Partners to Co-Create a Plan for HCV Elimination in Vancouver's Inner City

Nominated PICIHR2024Planning and Dissemination Grant - Institute Community Support

Principal investigators: Conway, Brian

Keywords: Community Partnerships; Hepatitis C Virus; Inner City; People Who Use Drugs

$19,986

Optimizing STBBI health outcomes through precision health

Co-investigatorCIHR2024T. Gr.: Embracing Diversity -HIV/AIDS/STBBI-Co-infections and Co-morbidities-LOI

Principal investigators: Janjua, Naveed Z; Wong, Jason; Bartlett, Sofia R; Krajden, Mel

Keywords: Chronic Non-Communicable Diseases; Co-Infections; Comorbidities; Hepatitis B; Hepatitis C; Hiv; Implementation Science; Precision Public Health; Syndemics; Syphilis

$20,000

Optimizing STBBI health outcomes through precision health

Co-investigatorCIHR2024Team Gr.:Embracing Diversity-HIV/AIDS and STBBI Co-infections and Co-morbidities

Principal investigators: Janjua, Naveed Z; Wong, Jason; Bartlett, Sofia R; Krajden, Mel

Keywords: Community Collaborative; Disease Burden; Geospatial Modelling; Health Equity; Intervention Evaluation; Linked Administrative Data; Population And Public Health; Precision Health; Sexually Transmitted And Bloodborne Infections; Syndemics Framework

$1,997,416

After the Cure: Measuring the full impacts of direct acting antivirals for people living with HIV/hepatitis C virus coinfection in Canada

Co-investigatorCIHR2022Project Grant

Principal investigators: Klein, Marina B

Keywords: Access To Care; Co-Infection; Cure; Direct Acting Antivirals; Fibrosis Progression; Health Outcomes; Hepatitis C Virus; Hiv; Prospective Cohort Study; Re-Infection

$100,000

After the Cure: Measuring the full impacts of direct-acting antivirals for people living with HIV/hepatitis C virus coinfection in Canada

Co-investigatorCIHR2022Project Grant

Principal investigators: Klein, Marina B

Keywords: Access To Care; Co-Infection; Cure; Direct Acting Antivirals; Fibrosis Progression; Health Outcomes; Hepatitis C Virus; Hiv; Prospective Cohort Study; Re-Infection

$1,587,376

Canadian Network on Hepatitis C (CanHepC): From Discovery to Implementation

Co-investigatorCIHR2021Hepatitis C Research

Principal investigators: Shoukry, Naglaa H; Dickie, Melisa C; Bruneau, Julie; Feld, Jordan J; Grimshaw, Jeremy M; Janjua, Naveed Z; King, Alexandra; Richardson, Christopher D

Keywords: Cascade Of Care; Diagnosis; Direct Acting Antivirals; Hepatitis C; Implementation Science; Long-Term Outcomes; Prevention; Priority Populations

Discovering immune pathways to successful aging in HIV infection

Co-investigatorCIHR2017Team Grant: HIV/AIDS Comorbidities Prevention and Healthy Living - LOI

Principal investigators: Durand, Madeleine; Margolese, Shari L; Bernard, Nicole F; Chartrand-Lefebvre, Carl; Chomont, Nicolas; Jenabian, Mohammad-Ali; Mansour, Samer; Tremblay, Cécile L; Tsoukas, Christos M

Keywords: Cardiovascular; Cohort Study; Frailty; Hiv; Immunology; Viral Reservoirs

$25,000

A Comprehensive Community-Based Approach to HIV and HCV Infections Among Vulnerable Inner City Populations

Nominated PICIHR2016Planning and Dissemination Grant - Institute Community Support

Principal investigators: Conway, Brian

Keywords: Community Workshops; Dtes; Engagement In Care; Hcv; Hiv; Vulnerable Populations

$20,000

The National CIHR Hepatitis C Network (NCHCN)

Co-investigatorCIHR2015Team Grant: National Hepatitis C Collaborative Network

Principal investigators: Shoukry, Naglaa H; Wong, Thomas; Bruneau, Julie; Feld, Jordan J; Krajden, Mel; Richardson, Christopher D

Keywords: Aboriginals; Hepatitis C; Liver Cancer; Liver Disease; People Who Inject Drugs; Public Health; Risk Factors; Therapy; Vaccines; Viral Transmission

The Coming Revolution in HCV Therapy: Will HIV-HCV co-infected patients really benefit?

Co-investigatorCIHR2014Operating Grant - Priority Announcement : Hepatitis C (bridge)

Principal investigators: Klein, Marina B

Keywords: Access To Treatment; Cost-Effectivness Analysis; Direct Antiviral Agents (Daas); End-Stage Liver Disease (Esld); Health Economics; Health Outcomes; Hepatitis C (Hcv); Hepatitis C Treatment; Hiv; Models Of Care

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Brian Conway

Research

Latest papers

Latest funding

Worldwide Impact of ACIP's 2025 Overhaul.

Addressing digital exclusion to improve access to HIV and viral hepatitis care for people who experience criminalization: a mixed methods evaluation of a quality improvement project.

Achieving the UNAIDS 95-95-95 targets: a right, not a privilege.

Understanding the clinical implications of low-level viremia in ART-treated individuals.

CHIME: Sofosbuvir/Velpatasvir (S/V) for the Treatment of HCV Infection Among Vulnerable Inner-City Residents.

Community Pop-Up Clinic: Cascade of Care and HCV Treatment of Vancouver's Inner-City PWID Populations.

Beyond virologic suppression.

The challenge of normalizing vaccine behaviors in the postpandemic era.

Long-term outcome in people who use drugs successfully treated for hepatitis C infection with glecaprevir/pibrentasvir.

Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis.

Engaging Community Partners to Co-Create a Plan for HCV Elimination in Vancouver's Inner City

Optimizing STBBI health outcomes through precision health

Optimizing STBBI health outcomes through precision health

After the Cure: Measuring the full impacts of direct acting antivirals for people living with HIV/hepatitis C virus coinfection in Canada

After the Cure: Measuring the full impacts of direct-acting antivirals for people living with HIV/hepatitis C virus coinfection in Canada

Canadian Network on Hepatitis C (CanHepC): From Discovery to Implementation

Discovering immune pathways to successful aging in HIV infection

A Comprehensive Community-Based Approach to HIV and HCV Infections Among Vulnerable Inner City Populations

The National CIHR Hepatitis C Network (NCHCN)

The Coming Revolution in HCV Therapy: Will HIV-HCV co-infected patients really benefit?

Frequent collaborators

Marina Klein

Julie Bruneau

Sofia Bartlett

Brian Conway

Research

Latest papers

Latest funding

Worldwide Impact of ACIP's 2025 Overhaul.

Addressing digital exclusion to improve access to HIV and viral hepatitis care for people who experience criminalization: a mixed methods evaluation of a quality improvement project.

Achieving the UNAIDS 95-95-95 targets: a right, not a privilege.

Understanding the clinical implications of low-level viremia in ART-treated individuals.

CHIME: Sofosbuvir/Velpatasvir (S/V) for the Treatment of HCV Infection Among Vulnerable Inner-City Residents.

Community Pop-Up Clinic: Cascade of Care and HCV Treatment of Vancouver's Inner-City PWID Populations.

Beyond virologic suppression.

The challenge of normalizing vaccine behaviors in the postpandemic era.

Long-term outcome in people who use drugs successfully treated for hepatitis C infection with glecaprevir/pibrentasvir.

Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Na&#xef;ve Patients with Compensated Cirrhosis.

Frequent collaborators

Marina Klein

Julie Bruneau

Sofia Bartlett

Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis.